临床PI
虞先濬 教授
教授,博士生导师
E-mail: yuxianjun88@hotmail.com
 

  虞先濬教授长期从事胰腺癌外科基础和临床转化研究,主要成绩为:①创新“胰空肠吻合”术式,将胰瘘率由国际平均的15%下降至7%;规范手术清扫范围及优化术后辅助化疗方案,使患者中位生存期较前提高约30%,达到国际先进水平。②建立术前血清生物标签“CEA+/CA125+/CA19-9≥1000U/mL”,甄别出“手术不获益”的胰腺癌亚群,从机制上阐释该人群的高代谢特征和特异性分子靶点。先后主持国家自然科学基金中德国际合作项目1项、面上项目3项,入选“上海市卫生系统新百人”、“上海市启明星”等人才计划,获明治生命科学“杰出奖”和上海市优秀发明选拔赛金奖。近5年以通讯/第一(含共同)作者发表Cell Res,Oncogene等50余篇SCI论文,作为第一发明人获6项国家专利,成果纳入多部胰腺癌临床诊治指南/共识。后续拟深入探索“手术不获益”胰腺癌亚群的分子特征和调控靶点,建立胰腺癌个体化外科综合治疗新策略。


研究领域:

  1.优化改善胰腺癌吻合技术进一步降低胰腺癌术后胰漏;
  2.开展外科微创腹腔镜技术引导下术中放疗的新方法,突破了传统放疗在胰腺癌上运用的局限性;
  3.探索胰腺癌淋巴转移特点,指导胰腺癌淋巴清扫并行针对性淋巴导向治疗;
  4.探索胰腺癌生物学特性,进一步转化应用于临床治疗。

研究团队:



代表性论著:

  1. Guopei Luo#, Chen Liu#, Meng Guo#, He Cheng, Yu Lu, Kaizhou Jin, Liang Liu, Jiang Long, Jin Xu, Renquan Lu, Quanxing Ni, Xianjun Yu*. Potential Biomarkers in Lewis Negative Patients with Pancreatic Cancer. Annals of Surgery, 2016 accepted.
  2. Shunrong Ji#, Yi Qin#, Chen Liang#, Run Huang, Si Shi, Jiang Liu, Kaizhou Jin, Dingkong Liang, Wenyan Xu, Bo Zhang, Liang Liu, Chen Liu, Jin Xu, Quanxing Ni, Paul J. Chiao, Min Li, Xianjun Yu*. FBW7 (F-box andWD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer. Clinical Cancer Research, 2016 accepted.
  3. Zhiwen Xiao#, Guopei Luo#, Zuqiang Liu, Kaizhou Jin, Jin Xu, Chen Liu, Liang Liu, Quanxing Ni,Jiang Long, Xianjun Yu*. Roux-en-Y pancreaticojejunostomy reconstruction after deep enucleation of benign or borderline pancreatic lesions: a single-institution experience. HPB (Oxford), 2016 Feb; 18(2):145-52. 
  4. Chen Liu#, Rufu Chen, Yingtai Chen, Deliang Fu, Defei Hong, Jihui Hao, Dawei Liu, Jiangtao Li, Shengping Li, Yixiong Li, Gang Mai, Yiping Mou, Quanxing Ni, Li Peng, Honggang Qian, Renyi Qin, Bei Sun, Chenghao Shao, Yongwei Sun, Bole Tian, Jian Wang, Wei Wang, Weilin Wang, Gang Zhao, Xianjun Yu*. Should a standard lymphadenectomy during pancreatoduodenectomy exclude para-aortic lymph nodes for all cases of resectable pancreatic head cancer? A consensus statement by the Chinese Study Group for Pancreatic Cancer (CSPAC). Int J Oncol, 2015 Oct; 47(4):1512-6.
  5. Liu Z#, Luo G#, Guo M, Jin K, Xiao Z, Liu L, Liu C, Xu J, Ni Q, Long J, Yu X*. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Pancreatology, 2015 May-Jun; 15(3):253-8.
  6. Jin K#, Luo G#, Xiao Z, Liu Z, Liu C, Ji S, Xu J, Liu L, Long J, Ni Q, Yu X*. Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug Des Devel Ther, 2015 Feb 26; 9:1247-55.
  7. Guopei Luo#, Zuqiang Liu#, Meng Guo, Kaizhou Jin, Zhiwen Xiao, Liang Liu, Chen Liu, Jin Xu, Quanxing Ni, Jiang Long, Xianjun Yu*. A comprehensive comparison of clinicopathologic and imaging features of incidental/symptomatic non-functioning pancreatic neuroendocrine tumors: A retrospective study of a single center. Pancreatology, 2015; 15(5):519-524.
  8. Xiang J#, Liu L#, Wang W, Xu H, Wu C, Xu J, Liu C, Long J, Ni Q, Yu X*. Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. Cancer Lett, 2015 Apr 10; 359(2):165-8.
  9. Guopei Luo#, Yu Lu#, Kaizhou Jin, He Cheng, Meng Guo, Zuqiang Liu, Jiang Long, Chen Liu, Quanxing Ni, Xianjun Yu*. Pancreatic cancer: BRCA mutation and personalized treatment. Expert Review of Anti-infective Therapy, 2015; 15(10):1223-1231.
  10. Xu Y#, Lu Y#, Cheng H#, Jiang J, Xu J, Long J, Liu L, Ni Q, Liu C, Yu X*. High Expression of Human Leukocyte Antigen-G is Associated with a Poor Prognosis in Patients with PDAC. Current Molecular Medicine, 2015; 15(4):360-7.
  11. Luo G#, Guo M#, Liu Z, Xiao Z, Jin K, Long J, Liu L, Liu C, Xu J, Ni Q, Yu X*. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Ann Surg Oncol, 2015 Feb; 22(2):670-6.
  12. Xu J#, Zhang B#, Shi S#, Qin Y, Ji S, Xu W, Liu J, Liu L, Liu C, Long J, Ni Q, Yu X*. Papillary-like main pancreatic duct invaginated pancreaticojejunostomy versus duct-to-mucosa pancreaticojejunostomy after pancreaticoduodenectomy: A prospective randomized trial. Surgery, 2015 Nov; 158(5):1211-8. 
  13. Tao Chen#, Min-Gui Zhang, Hua-Xiang Xu, Wen-Quan Wang, Liang Liu, Xian-Jun Yu*. Preoperative Serum CA125 Levels Predict the Prognosis in Hyperbilirubinemia Patients With Resectable Pancreatic Ductal Adenocarcinoma. Medicine, 2015; 94:1-10.
  14. Shunrong Ji#, Yi Qin#, Si Shi#, Xiangyuan Liu, Hongli Hu, Hu Zhou, Jing Gao, Bo Zhang, Wenyan Xu, Jiang Liu, Dingkong Liang, Liang Liu, Chen Liu, Jiang Long, Haijun Zhou, Paul J.Chiao, Jin Xu, Quanxing Ni, Daming Gao, Xianjun Yu*. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res, 2015 May; 25(5):561-73.
  15. Si Shi#, Shunrong Ji#, Yi Qin#, Jin Xu, Bo Zhang, Wenyan Xu, Jiang Liu, Jiang Long, Chen Liu, Liang Liu, Quanxing Ni, Xianjun Yu*. Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer. Cancer Lett, 2015 May 1; 360(2):227-33.
  16. Liu L#, Xu H#, Wang W#, Wu C#, Chen Y, Yang J, Cen P, Xu J, Liu C, Long J, Guha S, Fu D, Ni Q, Jatoi A, Chari S, McCleary-Wheeler AL, Fernandez-Zapico ME, Li M, Yu X*. A preoperative serum signature of CEA+ /CA125+ /CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer, 2014; 136(9):2216–2227.
  17. Wantong Yao#, Shunrong Ji#, Yi Qin#, Jingxuan Yang, Jin Xu, Bo Zhang, Wenyan Xu, Jiang Liu, Si Shi, Liang Liu, Chen Liu, Jiang Long, Quanxing Ni, Min Li, Xianjun Yu*. Profilin-1 suppresses tumorigenicity in pancreatic cancer through regulation of the SIRT3-HIF1α axis. Molecular Cancer, 2014 Aug 7; 13:187.
  18. GUOPEI LUO#, ZUQIANG LIU#, MENG GUO#, KAIZHOU JIN, ZHIWEN XIAO, LIANG LIU, JIN XU, BO ZHANG, CHEN LIU, DAN HUANG, SILONG HU, QUANXING NI, JIANG LONG, XIANJUN YU*.18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. INTERNATIONAL JOURNAL OF ONCOLOGY, 2014 Oct; 45(4):1531-6.
  19. Yong-Feng Xu#, Yu Lu#, He Cheng#, Si Shi, Jin Xu, Jiang Long, Liang Liu, Chen Liu, Xianjun Yu*. Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. Pancreatology, 2014 Jul-Aug; 14(4):295-301. 
  20. Wang WQ#, Liu L#, Xu HX#, Sun HC, Wu CT, Zhu XD, Zhang W, Xu J, Liu C, Long J, Ni QX, Tang ZY, Yu XJ*. The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib. Oncotarget, 2014 Jun 15; 5(11):3895-906.
  21. Long J#, Luo GP, Xiao ZW, Liu ZQ, Guo M, Liu L, Liu C, Xu J, Gao YT, Zheng Y, Wu CT, Ni QX, Li M, Yu XJ*. Cancer statistics: Current diagnosis and treatment of pancreatic cancer in Shanghai, China. Cancer Lett, 2014 May 1; 346(2):273-7.
  22. Qin Y#, Zhu WW#, Xu WY#, Zhang B, Shi S, Ji SR, Liu J, Long J, Liu C, Liu L, Xu J, Yu XJ*. LSD1 sustains pancreatic cancer growth via maintaining HIF1α-dependent glycolytic process. Cancer Lett, 2014 Jun 1; 347(2):225-32. 
  23. Xu HX#, Chen T#, Wang WQ#, Wu CT#, Liu C, Long J, Xu J, Zhang YJ, Chen RH, Liu L, Yu XJ*. Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. Eur J Nucl Med Mol Imaging, 2014 Jun; 41(6):1093-102.
  24. Lu Y#, Liu C#, Xu YF#, Cheng H, Shi S, Wu CT, Yu XJ*. Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition. Hepatobiliary Pancreat Dis Int, 2014; 13(4): 386-395.
  25. Lu Y#, Liu C#, Cheng H, Xu YF, Jiang JH, Xu J, Long J, Liu L, Yu XJ*. Stathmin, interacting with Nf-κB, promotes tumor growth and predicts poor prognosis of pancreatic cancer. Curr Mol Med, 2014 Mar; 14(3):328-39.
  26. Shi S, Lu Y, Qin Y, Li W, Cheng H, Xu YF, Xu J, Long J, Liu L, Liu C, Yu XJ*. miR-1247 is correlated with prognosis of pancreatic cancer and inhibits cell proliferation by targeting neuropilins. Curr Mol Med, 2014 Mar; 14(3):316-27.
  27. Jia-Hao Jiang#, Chen Liu#, He Cheng, Yu Lu, Yi Qin, Yong-Feng Xu, Jin Xu, Jiang Long, Liang Liu, Quan-Xing Ni, Xian-Jun Yu*. Epithelial–mesenchymal transition in pancreatic cancer: Is it a clinically significant factor? Biochimica et Biophysica Acta, 2015 Jan; 1855(1):43-9.
  28. Xiao ZW#, Luo GP#, Liu C, Wu CT, Liu L, Liu ZQ, Ni QX, Long J, Yu XJ*. Molecular Mechanism Underlying Lymphatic Metastasis in Pancreatic Cancer. BioMed Research International, 2014; 2014:925845. 
  29. Wu CT#, Xu WY#, Liu L, Long J, Xu J, Ni QX, Liu C, Yu XJ*. Ligamentum teres hepatis patch enhances the healing of pancreatic fistula after distal pancreatectomy. Hepatobiliary Pancreat Dis In, 2013 Dec; 12(6):651-5.
  30. Liu L#, Xu HX#, Wang WQ#, Wu CT#, Chen T, Qin Y, Liu C, Xu J, Long J, Zhang B, Xu YF, Ni QX, Li M, Yu XJ*. Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene, 2014 May 22; 33(21):2728-36. 
  31. Luo GP#, Xiao ZW#, Long J#, Liu ZQ, Liu L, Liu C, Xu J, Ni QX, Yu XJ*. CA125 is Superior to CA19-9 in Predicting the Resectability of Pancreatic Cancer. J Gastrointest Surg, 2013; 17(12): 2092-2098.
  32. Xu J#, Zhu WW#, Xu WY#, Yao WT, Zhang B, Xu YF, Ji SR, Liu C, Long J, Ni QX, Yu XJ*. Up-regulation of MBD1 Promotes Pancreatic Cancer Cell Epithelial-Mesenchymal Transition and Invasion by Epigenetic Down-regulation of E-cadherin. Curr Mol Med, 2013; 13(3): 387-400.
  33. Wang WQ#, Liu L#, Xu HX#, Luo GP, Chen T, Wu CT, Xu YF, Xu J, Liu C, Zhang B, Long J, Tang ZY, Yu XJ*. Intratumoral α-SMA Enhances the Prognostic Potency of CD34 Associated with Maintenance of Microvessel Integrity in Hepatocellular Carcinoma and Pancreatic Cancer. PLoS One, 2013; 5(8):71189.
  34. Zhang B#, Xu J#, Liu C, Long J, Liu L, Xu YF, Wu CT, Luo GP, Ni QX, Li M, Yu XJ*. Application of "papillary-like main pancreatic duct invaginated" pancreaticojejunostomy for normal soft pancreas cases. Sci Rep, 2013; 3(1): 2068-2073.
  35. Cheng H#, Li J#, Liu C#, Yao W, Xu Y, Frank TS, Cai X, Shi S, Lu Y, Qin Y, Liu L, Xu J, Long J, Ni QX, Li M, Yu XJ*. Profilin1 Sensitizes Pancreatic Cancer Cells to irradiation by Inducing Apoptosis and Reducing Autophagy. Curr Mol Med, 2013; 13(8):1368-1375.
  36. Chen T#, Liu L, Xu HX, Wang WQ, Wu CT, Yao WT, Yu XJ*. Significance of caveolin-1 regulators in pancreatic cancer. Asian Pac J Cancer Prev, 2013; 14(8):4501-4507.
  37. Liu C#, Cheng H#, Shi S#, Cui X, Yang J, Chen L, Cai XC, Lu Y, Wu CT, Yao WT, Qin Y, Liu L, Long J, Xu J, Li M, Yu XJ*. MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Curr Mol Med, 2013; 13(4): 467-478.
  38. Xu J#, Zhu WW#,  Xu WY#, Cui X, Chen L, Ji SR, Qin Y, Yao WT, Liu L, Liu C, Long J, Li M, Yu XJ*. Silencing MBD1 Reverses Pancreatic Cancer Therapy Resistance through Inhibiting DNA Damage Repair. Int J Oncol, 2013; 42(6): 2046-2052.
  39. Yao WT#, Cai XC#, Liu C#, Qin Y, Cheng H, Ji SR, Xu WY, Wu CT, Chen T, Xu J, Long J, Fang Z, Qu B, Hoth M, Ni QX, Zha XL, Yu XJ*. Profilin1 potentiates apoptosis induced by staurosporine in cancer cells. Curr Mol Med, 2013; 13(3): 417-428.
  40. Luo GP#, Long J#, Cui X, Xiao ZW, Liu ZQ, Shi S, Liu L, Liu C, Xu J, Li M, Yu XJ*. Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. Int J Oncol, 2013; 42(3):979-984.
  41. Liu C#, Long J, Liu L, Xu J, Zhang B, Yu XJ*, Ni QX. Pancreatic stump-closed pancreaticojejunostomy can be performed safely in normal soft pancreas cases. J Surg Res, 2012; 172(1):11-17.
  42. Long J#, Luo GP#, Liu C, Cui X, Satoh K, Xiao ZW, Zhang B, Xu J, Ni QX, Li M, Yu XJ*. Development of a unique mouse model for pancreatic cancer lymphatic metastasis. Int J Oncol, 2012; 41(5):1662-1668.
  43. Cheng H#, Shi S, Cai XC, Long J, Xu J, Liu C, Yu XJ*. microRNA signature for human pancreatic cancer invasion and metastasis. Exp Ther Med, 2012; 4(2):181-187.
  44. Luo GP#, Long J, Zhang B, Liu C, Xu J, Ni QX, Yu XJ*. Stroma and pancreatic ductal adenocarcinoma: An interaction loop. BBA-REV CANCER, 2012; 1826(1): 170-178.
  45. Ji SR#, Xu J#, Zhang B, Xu YF, Liu C, Long J, Ni QX, Yu XJ*. Management of a malignant case of solid pseudopapillary tumor of pancreas: a case report and literature review. Pancreas, 2012; 41(8): 1336-1340.
  46. Yao WT#, Yu XJ#, Fang Z, Yin P, Zhao C, Li N, Wang L, Li Z, Zha XL*. Profilin1 facilitates staurosporine-triggered apoptosis by stabilizing the integrin β1–actin complex in breast cancer cells. J Cell Mol Med, 2012; 4(16):824-835.
  47. Ji SR#, Xu J#, Zhang B, Yao WT, Xu WY, Wu W, Xu YF, Wang H, Ni QX, Hou H, Yu XJ*. RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy. Cancer Biol Ther, 2012; 13(4):206-215.
  48. Shi S#, Yao WT#, Xu J, Long J, Liu C, Yu XJ*. Combinational therapy: New hope for pancreatic cancer? Cancer Lett, 2012; 317(2):127-135.
  49. Luo GP#, Long J#, Zhang B, Liu C, Ji SR, Xu J, Yu XJ*, Ni Q. Quantum dots in cancer therapy. Expert Opin Drug Deliv, 2012; 9(1):47-58.
  50. Luo GP#, Long J#, Qiu L, Liu C, Xu J, Yu XJ*. Role of epidermal growth factor receptor expression on patient survival in pancreatic cancer: a meta-analysis. Pancreatology, 2011; 11(6):595-600.
  51. Ji SR#, Liu C, Zhang B, Yang F, Xu J, Long J, Jin C, Fu DL, Ni QX, Yu XJ*. Carbon nanotubes in cancer diagnosis and therapy. BBA-REV CANCER, 2010; 1806(1):29-35.
  52. Luo GP#, Long J, Zhang B, Liu C, Xu J, Yu XJ*, Ni Q. Developmental plasticity of stem cells and diseases. Med Hypotheses, 2010; 75(6):507-510.
  53. Yu XJ#, Zhang Y, Chen C, Yao Q, Li M*.Targeted drug delivery in pancreatic cancer. BBA-REV CANCER, 2010; 1805(1):97-104.
  54. Luo GP#, Yu XJ*, Jin C, Yang F, Fu DL, Long J, Xu J, Zhan C, Lu W. LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors. Int J Pharm, 2010; 385(1-2): 150-156.
 
复旦大学肿瘤研究所 通讯地址: 东安路270号2号楼1312室 64175590-5312 Email:fuci2012@126.com
Copyright 2013 shca.org.cn All rights reserved. 复旦大学肿瘤研究所 版权所有